 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || SB-318 / Sangamo Therap, SB-913 / Sangamo Therap, SB-FIX / Sangamo Therap
Enrollment closed: Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX (clinicaltrials.gov) - Feb 1, 2023
P=N/A, N=13, Active, not recruiting, Sponsor: Sangamo Therapeutics
Enrolling by invitation --> Active, not recruiting
- | SB-913 / Sangamo Therap
Journal: First Report of Armillaria root disease of Celtis laevigata caused by A. gallica in South Carolina, USA. (Pubmed Central) - May 12, 2022
Tree SB913 (N33 29.830, W81 59.349, elev...Plant Dis. 89:683.
- SB-913 / Sangamo Therap
Trial completion date, Trial termination: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II (clinicaltrials.gov) - Jun 8, 2021
P1/2, N=9, Terminated, Sponsor: Sangamo Therapeutics
89:683. Trial completion date: Jun 2022 --> May 2021 | Active, not recruiting --> Terminated; All nine subjects dosed in the study have rolled over to the Long-Term Follow-up Study IVPRP-LT01 [NCT04628871]
- SB-913 / Sangamo Therap
Trial completion date, Trial primary completion date: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II (clinicaltrials.gov) - Mar 2, 2021
P1/2, N=9, Active, not recruiting, Sponsor: Sangamo Therapeutics
Trial completion date: Jun 2022 --> May 2021 | Active, not recruiting --> Terminated; All nine subjects dosed in the study have rolled over to the Long-Term Follow-up Study IVPRP-LT01 [NCT04628871] Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2021 --> Jun 2021
- |||||| SB-318 / Sangamo Therap, SB-913 / Sangamo Therap, SB-FIX / Sangamo Therap
New trial: Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX (clinicaltrials.gov) - Nov 15, 2020
P, N=13, Enrolling by invitation, Sponsor: Sangamo Therapeutics
- ||| SB-913 / Sangamo Therap
Enrollment closed, Phase classification, Enrollment change: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II (clinicaltrials.gov) - Jul 2, 2019
P1/2, N=9, Active, not recruiting, Sponsor: Sangamo Therapeutics
Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2021 --> Jun 2021 Recruiting --> Active, not recruiting | Phase classification: P1 --> P1/2 | N=23 --> 9
- SB-913 / Sangamo Therap
Trial initiation date: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II (clinicaltrials.gov) - Jul 28, 2017
P1, N=9, Recruiting, Sponsor: Sangamo Therapeutics
Recruiting --> Active, not recruiting | Phase classification: P1 --> P1/2 | N=23 --> 9 Initiation date: Apr 2017 --> Jul 2017
- SB-913 / Sangamo Therap
Enrollment open: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II (clinicaltrials.gov) - Apr 25, 2017
P1, N=9, Recruiting, Sponsor: Sangamo Therapeutics
Initiation date: Apr 2017 --> Jul 2017 Not yet recruiting --> Recruiting
- SB-913 / Sangamo Therap
New P1 trial: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II (clinicaltrials.gov) - Feb 2, 2017
P1, N=9, Not yet recruiting, Sponsor: Sangamo Therapeutics